Nikolin Borislava, Djan Igor, Trifunovic Jasna, Dugandzija Tihomir, Novkovic Dejan, Djan Vladimir, Vucinic Natasa
Institute of Oncology Vojvodina, Sremska Kamenica, Serbia.
J BUON. 2016 May-Jun;21(3):691-7.
Melanoma represents the most severe form of skin cancer. Detection of specific tumor markers is an important step in disease diagnosis and treatment, contributing to personalized therapy. The purpose of this study was to evaluate the potential of MIA, S-100 and LDH as biomarkers for the estimation of overall survival and disease-free survival rate in patients with stage IIa, IIb vs stage IIc melanoma.
Selected biomarkers MIA, S-100 and LDH were prospectively evaluated in 80 patients with melanoma. Patients were divided in two groups according to tumor thickness. The first group (group A) consisted of patients with primary tumor thickness between 2.0 - 4.0 mm (N=40), i.e. IIa and IIb stage of disease (16 males; 40%, and 24 females; 60%). The second group (group B) consisted of 40 patients with primary tumor thickness over 4.0 mm, i.e. IIc stage, which is considered as high risk group (26 males; 65%, and 14 females 35%). Statistical analyses were performed to estimate overall survival and disease-free survival in both patient groups.
In group A a significant difference in overall survival was found among MIA1, MIA2 and MIA3 scores, while the other 2 markers didn't show significant differences. In group B statistically significant differences in overall survival were found regarding all three biomarkers. Statistically significant differences in disease-free survival were found for MIA1 score compared to MIA2 and MIA3 scores. Also, very significant difference was detected in patients with S-100 below 0.106 and above 0.106. The same was confirmed for normal and increased LDH level in group B for disease-free survival.
MIA score, S100 protein and LDH in the IIC group B patients might be useful in the prediction of overall survival and disease free survival.
黑色素瘤是最严重的皮肤癌形式。检测特定肿瘤标志物是疾病诊断和治疗的重要步骤，有助于个性化治疗。本研究的目的是评估黑色素瘤IIa、IIb期与IIc期患者中，黑色素瘤抑制活性（MIA）、S-100和乳酸脱氢酶（LDH）作为生物标志物用于评估总生存期和无病生存率的潜力。
对80例黑色素瘤患者前瞻性评估选定的生物标志物MIA、S-100和LDH。根据肿瘤厚度将患者分为两组。第一组（A组）由原发性肿瘤厚度在2.0 - 4.0毫米之间的患者组成（N = 40），即疾病的IIa和IIb期（男性16例；40%，女性24例；60%）。第二组（B组）由40例原发性肿瘤厚度超过4.0毫米的患者组成，即IIc期，这被视为高危组（男性26例；65%，女性14例；35%）。进行统计分析以评估两组患者的总生存期和无病生存期。
在A组中，MIA1、MIA2和MIA3评分之间的总生存期存在显著差异，而其他2种标志物未显示出显著差异。在B组中，所有三种生物标志物的总生存期均存在统计学显著差异。与MIA2和MIA3评分相比，MIA1评分的无病生存期存在统计学显著差异。此外，S-100低于0.106和高于0.106的患者之间检测到非常显著的差异。B组中正常和升高的LDH水平对无病生存期的影响也得到了证实。
B组IIc期患者的MIA评分、S100蛋白和LDH可能有助于预测总生存期和无病生存期。
